Your browser is no longer supported. Please, upgrade your browser.
Ascendis Pharma A/S
Index- P/E- EPS (ttm)-8.86 Insider Own0.03% Shs Outstand52.72M Perf Week-9.59%
Market Cap7.90B Forward P/E- EPS next Y-6.22 Insider Trans0.00% Shs Float6.00M Perf Month-5.10%
Income-438.80M PEG- EPS next Q-1.55 Inst Own- Short Float36.87% Perf Quarter-14.93%
Sales10.90M P/S724.88 EPS this Y-48.00% Inst Trans1.40% Short Ratio11.69 Perf Half Y-0.42%
Book/sh21.98 P/B6.53 EPS next Y9.50% ROA-49.60% Target Price191.77 Perf Year7.85%
Cash/sh20.55 P/C6.98 EPS next 5Y24.00% ROE-56.00% 52W Range92.00 - 183.98 Perf YTD-13.99%
Dividend- P/FCF- EPS past 5Y-61.90% ROI-35.70% 52W High-22.03% Beta0.79
Dividend %- Quick Ratio14.80 Sales past 5Y-0.90% Gross Margin- 52W Low55.92% ATR6.61
Employees330 Current Ratio14.80 Sales Q/Q27.30% Oper. Margin- RSI (14)35.98 Volatility4.85% 4.12%
OptionableYes Debt/Eq0.03 EPS Q/Q-337.60% Profit Margin- Rel Volume3.19 Prev Close152.90
ShortableYes LT Debt/Eq0.03 Earnings- Payout- Avg Volume189.15K Price143.45
Recom1.50 SMA20-7.73% SMA50-10.63% SMA200-6.72% Volume577,520 Change-6.18%
Dec-17-20Initiated Berenberg Buy $216
Sep-14-20Resumed JP Morgan Overweight $160
Mar-20-20Initiated Oppenheimer Outperform $199
Oct-11-19Initiated Morgan Stanley Overweight $128
Mar-25-19Initiated Evercore ISI Outperform
Jan-24-19Upgrade Leerink Partners Mkt Perform → Outperform
Jan-24-19Initiated Cantor Fitzgerald Overweight $102
Jun-26-18Initiated Stifel Buy $85
Apr-02-18Reiterated Leerink Partners Mkt Perform $37 → $64
May-11-17Initiated JP Morgan Overweight $36
Mar-09-17Downgrade Leerink Partners Outperform → Mkt Perform
Feb-09-17Initiated Credit Suisse Outperform $28
Sep-26-16Initiated Wedbush Outperform $34
Mar-04-21 04:05PM  
Feb-26-21 07:05AM  
Feb-18-21 04:05PM  
Jan-14-21 08:29AM  
Jan-13-21 11:02AM  
Jan-10-21 07:04PM  
Jan-08-21 10:06PM  
Jan-04-21 07:05AM  
Dec-30-20 04:05PM  
Dec-14-20 04:05PM  
Nov-25-20 07:05AM  
Nov-15-20 07:20AM  
Nov-11-20 05:30PM  
Nov-10-20 08:40AM  
Nov-04-20 10:12AM  
Nov-03-20 07:05AM  
Nov-02-20 04:05PM  
Oct-23-20 08:05AM  
Oct-21-20 05:51PM  
Oct-08-20 06:40PM  
Sep-29-20 11:04AM  
Sep-28-20 07:00PM  
Sep-23-20 04:05PM  
Sep-15-20 05:45PM  
Sep-11-20 07:05AM  
Sep-10-20 07:05AM  
Sep-08-20 04:44PM  
Sep-04-20 08:30AM  
Sep-02-20 04:05PM  
Aug-27-20 10:00PM  
Aug-21-20 09:48AM  
Aug-13-20 04:01PM  
Aug-12-20 07:05AM  
Aug-04-20 08:30AM  
Jul-24-20 09:47AM  
Jul-10-20 08:49PM  
Jul-07-20 10:11PM  
Jul-06-20 12:58PM  
Jun-29-20 11:44AM  
Jun-26-20 08:29AM  
Jun-22-20 08:30AM  
Jun-10-20 12:27PM  
Jun-08-20 08:15AM  
Jun-03-20 03:46PM  
May-29-20 09:28PM  
May-22-20 06:14AM  
May-19-20 04:01PM  
May-11-20 08:30AM  
May-08-20 11:46AM  
May-07-20 04:01PM  
Apr-21-20 06:01AM  
Apr-19-20 04:00PM  
Apr-16-20 09:40PM  
Apr-15-20 04:58PM  
Apr-01-20 04:01PM  
Mar-25-20 04:01PM  
Mar-22-20 08:25PM  
Mar-21-20 08:49AM  
Mar-17-20 12:00PM  
Feb-12-20 04:01PM  
Feb-10-20 09:28AM  
Feb-06-20 10:44AM  
Feb-04-20 11:28AM  
Jan-21-20 05:21AM  
Jan-12-20 07:45PM  
Jan-09-20 04:00PM  
Dec-26-19 11:26AM  
Dec-06-19 11:57PM  
Dec-04-19 12:42PM  
Nov-22-19 05:38AM  
Nov-21-19 09:05AM  
Nov-18-19 04:01PM  
Nov-14-19 04:01PM  
Nov-12-19 09:52AM  
Nov-11-19 07:50AM  
Nov-08-19 04:02PM  
Nov-06-19 04:02PM  
Nov-05-19 11:50AM  
Nov-04-19 06:30PM  
Oct-29-19 09:00AM  
Oct-24-19 11:47AM  
Oct-21-19 04:04PM  
Oct-14-19 08:44PM  
Oct-01-19 03:50PM  
Ascendis Pharma A/S, a biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon growth hormone, which has completed Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone which is in Phase II clinical study for treating hypoparathyroidism; and TransCon CNP, a long-acting prodrug of C-type natriuretic peptide which is in Phase II clinical for the treatment of achondroplasia. It is also developing preclinical studies in the field of oncology for potential product candidates and evaluate systemic and localized delivery systems using its TransCon technologies. It also has strategic collaborations with Sanofi to develop TransCon technologies for the treatment of diabetes. The company was founded in 2006 and is headquartered in Hellerup, Denmark.